The Louvain Drug Research Institute (LDRI) at UCL has a multidisciplinary research expertise in the field of nanomedecine, including formulation and use for diagnosis, therapeutics and regenerative medicine. Internationally-recognized laboratories of drug delivery / pharmaceutics, cancer, magnetic resonance imaging are involved in the proposal and collaborate on nanomedicine with chemistry and clinical labs.
LDRI at UCL has long-standing experience in the training of PhD students which are supervised by doctoral committees. The PhD students studying at UCL are in contact with an international scientific community, and can develop new competences (scientific communication, project management, working within networks … ). It is well-organised to welcome foreign PhD students: among the 50 PhD students registered, one third are foreign visitors.

Role in the NanoFar consortium
LDRI at UCL, as a partner of the EMJD NanoFar, will actively participate in the supervisory and management boards so as to ensure good coordination between all the NanoFar partners.
UCL will dedicate 2 PhD to this supervision, a member of administrative staff to the project management and a financial staff for the reallocation of the Erasmus Mundus fellowships to PhD candidates.

LDRI at UCL has selected putative PhD Supervisors with excellent track records. These supervisors will act in the twinning PhD project. UCL will support the PhD candidates enrolled in its institution in their visa process and their integration in the campus and offer services such as language training.
LDRI at UCL is committed to organise a doctoral school once in the PhD curriculum and to give support to other schools organised in the other partner institutions. It will offer students the option to enroll in existing and established optional PhD courses throughout the academic year.

Website: Université catholique de Louvain